Protocol Ledger

NCT06839066 · Phase II · RECRUITING

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Interventional Phase II clinical trial protocol NCT06839066 sponsored by Shanghai Henlius Biotech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-02 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06839066
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06839066
Protocol FieldVerified Registry Value
NCT IdentifierNCT06839066
Consolidated Lead SponsorShanghai Henlius Biotech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2025-04-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06839066
Hospital Research SiteLocationSite Profile
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Dongguan People's HospitalDongguan, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Guangxi Medical University Cancer HospitalNanning, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI